Posters
« Back
Mesenchymal Stem Cells And Exosome Therapy for COVID‑19: Current Status and Future Perspective
EP39028
Poster Title: Mesenchymal Stem Cells And Exosome Therapy for COVID‑19: Current Status and Future Perspective
Submitted on 12 Jul 2022
Author(s): Shraddha Singh Gautam
Affiliations: Advancells Stem Cell Therapy Center
This poster was presented at Stem Cells And Exosome Therapy
Poster Views: 126
View poster »


Poster Information
Abstract: Acute respiratory distress syndrome (ARDS) is the main cause for the COVID-19 infection-related morbidity and mortality. Recent clinical evidences suggest increased level of cytokines and chemokines targeting lung tissue as a prominent etiological factor. The immunomodulatory effect of mesenchymal stem cells (MSCs) as the alternative therapy for the treatment of inflammatory and autoimmune diseases is well known. Several studies have also revealed that similar therapeutic impacts of parent MSCs are also exhibited by MSCs-derived extracellular vesicles (EVs) including exosomes. In this review, we explored the therapeutic potential of both MSCs and exosomes in mitigating the COVID-19 induced cytokine storm as well as promoting the regeneration of alveolar tissue, attributed to the intrinsic cytokines and growth factor present in the secretome. The preliminary studies have demonstrated the safety and efficacy of MSCs and exosomes in mitigating symptoms associated with COVID-19. Thus, they can be used on compassionate basis, owing to their ability to endogenously repair and decrease the inflammatory reactions involved in the morbidity and mortality of COVID-19. However, more preclinical and clinical studies are warranted to understand their mechanism of action and further establish their safety and efficacy.Summary: COVID-19 is currently one of the biggest socio-economic and public health dangers that we have seen. With the hope of vaccine that will eradicate the viral infection still in the distant future, there is an urgent need for treatments that are not only efficacious but safe. Preliminary studies have demonstrated the safety and efficacy of MSCs and exosomes in mitigating symptoms associated with COVID-19. They can be used on compassionate basis, owing to their ability to endogenously repair and decReferences: 1.COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [Internet]. [cited 2020 Jul 1]. Available from: https://coronavirus.jhu.edu/map.html
2. Zhao RC. Stem cell – based therapy for coronavirus disease 2019. Stem Cells Dev. 2020;29:679–681. doi: 10.1089/scd.2020.0071. - DOI - PMC - PubMed
3. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2 - Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. J Aging Dis. 2020;11:216–228. doi: 10.14336/AD.2020.0228. - DOI - PMC - PubMed
4. Mangalmurti N, Hunter CA. Primer cytokine storms: understanding COVID-19. Immunity. 2020;53:19–25. doi: 10.1016/j.immuni.2020.06.017. - DOI - PMC - PubMed
5. Hossein G, Zohreh M, Hedayat J, Zahra S. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID - 19 infection: the contribution of “ inlame - aging”. Inflamm Res. 2020;11:1–15. - PMC - PubMed
6. Murt
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons